Clinical Trial Update: An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments [Phase 1]

View source ↗

Summary

Phase 1 open-label, dose-escalation study in Japanese patients with relapsed/refractory multiple myeloma who have failed prior anti-myeloma therapies; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2025-04-10